|
Squamous cell carcinoma of lung
|
0.310 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods</b>: In this study, we evaluated for the first time the prognostic value of Plk1 mRNA and protein expression in combination with the <i>TP53</i> mutation status (next generation sequencing), induction of apoptotic cell death (immunohistochemistry for cleaved caspase 3) and hypoxia (immunohistochemistry for carbonic anhydrase IX (CA IX)) in 98 NSCLC adenocarcinoma patients.
|
28638459 |
2017 |
|
Epithelial ovarian cancer
|
0.040 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Acquired resistance to cisplatin is a major barrier to success in treatment of various cancers, and understanding mitotic mechanisms unique to cisplatin-resistant cancer cells can provide the basis for developing novel mitotic targeted therapies aimed at eradicating these cells.<b>Experimental Design:</b> Using cisplatin-resistant models derived from primary patient epithelial ovarian cancer (EOC) cells, we have explored the status of mitotic exit mechanisms in cisplatin-resistant cells.<b>Results:</b> We have uncovered an unexpected role of long-term cisplatin treatment in inducing mitotic exit vulnerability characterized by increased spindle checkpoint activity and functional dependency on Polo-like kinase 1 (PLK1) for mitotic exit in the presence of anaphase promoting complex/cyclosome (APC/C) dysfunction in a cisplatin-resistant state.
|
29653924 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.040 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Acquired resistance to cisplatin is a major barrier to success in treatment of various cancers, and understanding mitotic mechanisms unique to cisplatin-resistant cancer cells can provide the basis for developing novel mitotic targeted therapies aimed at eradicating these cells.<b>Experimental Design:</b> Using cisplatin-resistant models derived from primary patient epithelial ovarian cancer (EOC) cells, we have explored the status of mitotic exit mechanisms in cisplatin-resistant cells.<b>Results:</b> We have uncovered an unexpected role of long-term cisplatin treatment in inducing mitotic exit vulnerability characterized by increased spindle checkpoint activity and functional dependency on Polo-like kinase 1 (PLK1) for mitotic exit in the presence of anaphase promoting complex/cyclosome (APC/C) dysfunction in a cisplatin-resistant state.
|
29653924 |
2018 |
|
Mammary Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
<i>In vitro</i> transfection of PLK1 and HSF1 siRNA into PKL1- and HSF1-positive human breast tumor MDA-MB-231 and human cervical carcinoma HeLa cells inhibited cell growth via suppression of PLK1 and HSF1 mRNA expression, respectively.
|
29067111 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor cell cycle arrest at the cell cycle G2/M boundary after ionizing radiation involves inhibition of the Polo-like kinase 1 (Plk1).
|
15160994 |
2004 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.
|
15173270 |
2004 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.
|
15173270 |
2004 |
|
Neck Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
PLK1 overexpression is a negative prognostic factor in patients suffering from non-small cell lung cancer, head and neck tumors, esophageal carcinomas and melanomas.
|
12082631 |
2002 |
|
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
PLK1 overexpression is a negative prognostic factor in patients suffering from non-small cell lung cancer, head and neck tumors, esophageal carcinomas and melanomas.
|
12082631 |
2002 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PLK1 overexpression is a negative prognostic factor in patients suffering from non-small cell lung cancer, head and neck tumors, esophageal carcinomas and melanomas.
|
12082631 |
2002 |
|
Cystadenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PLK 1 and PLK3 expression was low in normal ovarian surface epithelium and borderline tumours, with moderately higher expression levels in cystadenomas.
|
14970859 |
2004 |
|
Malignant neoplasm of urinary bladder
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
PLK-1 siRNA was successfully transfected into the cells, reduced PLK-1 expression, and prevented the growth of bladder cancer in this mouse model.
|
15761500 |
2005 |
|
Bladder Neoplasm
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
PLK-1 siRNA was successfully transfected into the cells, reduced PLK-1 expression, and prevented the growth of bladder cancer in this mouse model.
|
15761500 |
2005 |
|
Carcinoma of bladder
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
PLK-1 siRNA was successfully transfected into the cells, reduced PLK-1 expression, and prevented the growth of bladder cancer in this mouse model.
|
15761500 |
2005 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Polo-like kinase 1 (Plk1) is required for multiple stages of mitosis and is up-regulated in many human malignancies.
|
15805268 |
2005 |
|
Colon Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
PLK1 ASODN can induce apoptosis of human colon cancer cell line SW480.
|
16052696 |
2005 |
|
Malignant tumor of colon
|
0.050 |
Biomarker
|
disease |
BEFREE |
PLK1 ASODN can induce apoptosis of human colon cancer cell line SW480.
|
16052696 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Plk1 is over-expressed in many tumor types with aberrant elevation frequently constituting a prognostic indicator of poor disease outcome.
|
16223707 |
2005 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PLK1 is a new prognostic marker for colon carcinoma patients and may be involved in tumorigenesis and progression of colon cancer.
|
16237758 |
2005 |
|
Malignant tumor of colon
|
0.050 |
Biomarker
|
disease |
BEFREE |
PLK1 is a new prognostic marker for colon carcinoma patients and may be involved in tumorigenesis and progression of colon cancer.
|
16237758 |
2005 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PLK1 is overexpressed in human tumours and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target.
|
16557283 |
2006 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PLK1 is overexpressed in human tumours and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target.
|
16557283 |
2006 |
|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
PLK1 is overexpressed in human tumours and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target.
|
16557283 |
2006 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PLK1 expression may be a critical indicator of a poor prognosis in patients with gastric carcinoma.
|
16645325 |
2006 |